Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
01 mars 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
27 févr. 2023 17h19 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its...
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
22 févr. 2023 21h48 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its...
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
22 févr. 2023 07h22 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
21 févr. 2023 16h13 HE
|
Apellis Pharmaceuticals, Inc.
SYFOVRE™ (pegcetacoplan injection) approved in the U.S. as the first and only treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)EU marketing authorization...
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
17 févr. 2023 16h06 HE
|
Apellis Pharmaceuticals, Inc.
SYFOVRE slowed GA progression with increasing effects over time Approved for all patients with GA, with dosing flexibility every 25 to 60 days Well-demonstrated safety profile following ~12,000...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 févr. 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 janv. 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
05 janv. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina...
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...